Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Arfolitixorin

PreclinicalSmall molecule

IIsofol Medical AB

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal Cancer (mcrc)Recruiting

Metastatic Colorectal Cancer (mcrc)Preclinical

Recruiting

Timeline

Expected Milestones

Q4 2029

PreclinicalRecruiting

Metastatic Colorectal Cancer (mcrc)

NCT06922383

Clinical

Trials by Indication[1]

Liver Metastases1 trial

Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate

Unknown status·VVastra Gotaland Region·Phase 1/2·NCT04126655·30 enrolled

Colorectal Cancer1 trial

A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer

Completed·IIsofol Medical AB·Phase 3·NCT03750786·490 enrolled

Metastatic Colorectal Cancer (mCRC)1 trial

A Phase 1b/2 Study of Arfolitixorin as Part of 5-fluorouracil-based Treatment Regimens in the First-line Treatment of Metastatic Colorectal Cancer

Recruiting·IIsofol Medical AB·Preclinical·NCT06922383·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Arfolitixorin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Arfolitixorin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Arfolitixorin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Isofol Medical AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIsofol Medical AB

Related News